Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet F Eary

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
Cancer|July 13, 2002
Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomographyDouglas S Hawkins, Joseph G Rajendran, Ernest U Conrad, et al.
Cancer|June 12, 2009
[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adultsDouglas S Hawkins, Ernest U Conrad, James E Butrynski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2002
High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimationJoseph G Rajendran, Janet F Eary, William Bensinger, et al.
The Annals of Applied Statistics|November 14, 2014
VOXEL-LEVEL MAPPING OF TRACER KINETICS IN PET STUDIES: A STATISTICAL APPROACH EMPHASIZING TISSUE LIFE TABLESFinbarr O'Sullivan, Mark Muzi, David A Mankoff, et al.
The Journal of Bone and Joint Surgery. American Volume|January 17, 2014
Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcomeJanet F Eary, Ernest U Conrad, Janet O'Sullivan, et al.
Molecular Imaging and Biology|June 11, 2008
NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studiesAlexander M Spence, Mark Muzi, Jeanne M Link, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 23, 2002
Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysisJanet F Eary, Finbarr O'Sullivan, Yudi Powitan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2004
Comparison of different quantitative approaches to 18F-fluoride PET scansWinfried Brenner, Cheryl Vernon, Mark Muzi, et al.
British Journal of Sports Medicine|January 10, 2012
Sport Concussion Assessment Tool-2: baseline values for high school athletesThomas M Jinguji, Viviana Bompadre, Kimberly G Harmon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2004
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumesJoseph G Rajendran, Darrell R Fisher, Ajay K Gopal, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Cancer|July 13, 2002
Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomographyDouglas S Hawkins, Joseph G Rajendran, Ernest U Conrad, et al.
Cancer|June 12, 2009
[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adultsDouglas S Hawkins, Ernest U Conrad, James E Butrynski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2002
High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimationJoseph G Rajendran, Janet F Eary, William Bensinger, et al.
The Annals of Applied Statistics|November 14, 2014
VOXEL-LEVEL MAPPING OF TRACER KINETICS IN PET STUDIES: A STATISTICAL APPROACH EMPHASIZING TISSUE LIFE TABLESFinbarr O'Sullivan, Mark Muzi, David A Mankoff, et al.
The Journal of Bone and Joint Surgery. American Volume|January 17, 2014
Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcomeJanet F Eary, Ernest U Conrad, Janet O'Sullivan, et al.
Molecular Imaging and Biology|June 11, 2008
NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studiesAlexander M Spence, Mark Muzi, Jeanne M Link, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 23, 2002
Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysisJanet F Eary, Finbarr O'Sullivan, Yudi Powitan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2004
Comparison of different quantitative approaches to 18F-fluoride PET scansWinfried Brenner, Cheryl Vernon, Mark Muzi, et al.
British Journal of Sports Medicine|January 10, 2012
Sport Concussion Assessment Tool-2: baseline values for high school athletesThomas M Jinguji, Viviana Bompadre, Kimberly G Harmon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2004
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumesJoseph G Rajendran, Darrell R Fisher, Ajay K Gopal, et al.
Pageof 8